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Background: Nissen and Wolski recently updated their 2007 meta-analysis (56 trials, n= 35,531) by reporting that rosiglitazone (Rosi) was 
associated with a 28% greater risk of MI. However, the previously reported risk of CV death was no longer evident.
Objective: The investigators excluded 15 trials from MI and 29 trials from CV death analysis in which no events were observed. We sought to 
determine if these exclusions biased the results.
Methods: We compared the index study to meta-analyses of the entire 56 trials using different pooling methods with and without continuity 
corrections that adjust for values of zero: a constant correction (CC) that adds values of 1/2; a variable correction (VC) that adds a value of 1/n, 
where n is the sample size of opposite treatment arm.
Results (Table): The odds ratios (OR) ranged from 1.17 to 1.28 for MI and from 0.94 to 1.03 for CV death. Corrected models resulted in smaller OR 
and narrower confidence intervals than did uncorrected models. Although corrected risks remain elevated, none are statistically significant, except 
for the “treat as one trial” method employed by the authors that is prone to bias. Excluding the results of hypothesis-generating DREAM trial or 7 
trials where Rosi is not indicated or contraindicated yielded nonsignificant ORs.
Conclusions: Given the fragility of the data, there is insufficient evidence to either incriminate or exonerate the drug. Additional data will be 
required to adjudicate these inconclusive results. 
Method No. of trials MI p No. of trials CV Death p
Nissen-Wolski (Peto) 41 1.28 (1.02-1.63) 0.04 27 1.03 (0.78-1.36) 0.86
Nissen-Wolski (Peto) (-DREAM) 40 1.16 (0.91-1.47) 0.23 26 0.93 (0.69-1.24) 0.60
Corrected analyses using pooling according to randomization ratios
Nissen-Wolski (MH) 56 1.28 (1.01-1.62) 0.04 56 0.99 (0.75-1.32) 0.94
Corrected analyses using constant continuity correction (CC)
MH (CC) 56 1.19 (0.96-1.48) 0.12 56 0.95 (0.74-1.23) 0.72
IV (CC) 56 1.19 (0.95-1.49) 0.13 56 0.94 (0.73-1.21) 0.64
Bayesian (CC) 56 1.17 (0.94-1.46) - 56 0.96 (0.80-1.16) -
Corrected analyses using variable continuity correction (VC)
MH (VC) 56 1.25 (1.00-1.55) 0.051 56 1.02 (0.79-1.31) 0.87
IV (VC) 56 1.23 (0.98-1.57) 0.07 56 0.99 (0.77-1.29) 0.99
Bayesian (VC) 56 1.22 (0.98-1.52) - 56 1.00 (0.77-1.29) -
Minus 7 non-diabetic and CHF trials
Peto 37 1.26 (0.99-1.60) 0.06 22 1.01 (0.76-1.35) 0.95
MH (CC) 49 1.18 (0.95-1.48) 0.14 55 0.95 (0.73-1.23) 0.71
MH (VC) 49 1.23 (0.98-1.54) 0.07 55 1.01 (0.78-1.31) 0.95
MH = Mantel-Haenszel; IV = inverse variance
